Insmed (INSM) EBITDA Margin (2010 - 2026)
Insmed (INSM) recorded quarterly EBITDA Margin of 53.93% in Q1 2026, up 56.75% quarter-over-quarter from 124.7% in Q4 2025, and up 22099.0% on a YoY basis from N/an in Q1 2025.
Insmed (INSM) EBITDA Margin (2010 - 2026) Analysis & Trends
Insmed's EBITDA Margin history runs 12 years deep, the most recent figure standing at 53.93% for Q1 2026.
- In Q1 2026, EBITDA Margin rose 22099.0% year-over-year to 53.93%; the TTM figure through Mar 2026 stood at 144.33% (up 12141.0% YoY), while the FY2025 annual figure was 209.92%, up 4174.0% from the prior year.
- EBITDA Margin was 53.93% for Q1 2026 at Insmed, up from 124.7% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 53.93% in Q1 2026 to a low of 334.07% in Q2 2024.
- Historically, EBITDA Margin has averaged 222.97% across 5 years, with a median of 228.25% in 2024.
- The sharpest annual moves came in 2023 and 2026: EBITDA Margin plunged 17229 bps in 2023, then surged 22099 bps in 2026.
- A 5-year view of EBITDA Margin shows it stood at 266.41% in 2022, then gained by 17 bps to 220.72% in 2023, then fell by 3 bps to 228.25% in 2024, then jumped by 45 bps to 124.7% in 2025, then jumped by 57 bps to 53.93% in 2026.
- The last three EBITDA Margin figures came in at 53.93% (Q1 2026), 124.7% (Q4 2025), and 259.77% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | -6.43% |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Insmed | 19.79 Bn | 18.57 Bn | 258.54 Mn | -53.93% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -53.93% |
| Dec 31, 2025 | -124.70% |
| Sep 30, 2025 | -259.77% |
| Jun 30, 2025 | -297.03% |
| Mar 31, 2025 | -274.93% |
| Dec 31, 2024 | -228.25% |
| Sep 30, 2024 | -232.43% |
| Jun 30, 2024 | -334.07% |
| Mar 31, 2024 | -209.25% |
| Dec 31, 2023 | -220.72% |
| Sep 30, 2023 | -202.04% |
| Jun 30, 2023 | -320.01% |
| Mar 31, 2023 | -244.48% |
| Dec 31, 2022 | -266.41% |
| Sep 30, 2022 | -194.30% |
| Jun 30, 2022 | -147.72% |
| Mar 31, 2022 | -180.43% |
| Dec 31, 2021 | -199.75% |
| Sep 30, 2021 | -241.76% |
| Jun 30, 2021 | -257.87% |